Kanvas Biosciences has moved its laboratory operations to a 12,000-square-foot space at The HELIX in downtown New Brunswick, where the microbiome therapeutics company is advancing drug candidates and its research platform.
The company occupies the 10th floor of H-1, The HELIX’s flagship research building. Kanvas said the new lab will provide room for its team to advance its pipeline and platform partnerships.
Kanvas is developing live biotherapeutic products, or defined communities of bacteria, intended to affect the gut microbiome and help the immune system fight disease. Its work focuses in part on improving responses to immune checkpoint inhibitors, a form of cancer immunotherapy that does not work for all patients.
The company’s spatial biology platform uses imaging technology developed at Cornell University to map the location of microbes in the gut and their interactions with each other and human cells. Kanvas uses those findings to design potential microbiome treatments.
Its lead candidate, KAN-001, is being developed for cancer patients who require immune checkpoint inhibitors for non-small cell lung cancer. The company said it is preparing to begin recruitment this year. KAN-004 is recruiting patients for a Phase 1 trial for colitis caused by immune checkpoint inhibitor treatment.
A third candidate, KAN-007, is a fully synthetic microbiome replacement product being developed for environmental enteric dysfunction, a gut condition that the company says affects millions of children worldwide. The effort received support from the Gates Foundation.
The candidates are investigational and have not been approved by the U.S. Food and Drug Administration, the company said.
Kanvas closed a $48 million Series A financing in May 2026, co-led by DCVC and Lions Capital. The financing brought the company’s total funding to $78 million.
“This is a defining moment for Kanvas. We have new capital, a growing pipeline and a team ready to bring our science to patients,” said Matthew Cheng, co-founder and CEO. “New Jersey has a long history of life sciences leadership and The HELIX is where that next chapter is being written. We’re proud to be part of it, alongside a medical school and health systems that share our focus on patients.”
Kanvas joins a mix of health care, research and business organizations at The HELIX, including Rutgers Robert Wood Johnson Medical School, Hackensack Meridian Health, RWJBarnabas Health, Rutgers University and Aquestive Therapeutics, according to the release. The site also includes the New Jersey Innovation Hub Powered by Portal.
Christopher J. Paladino, president of the New Brunswick Development Corp. and CEO of HELIX, said Kanvas’s arrival strengthens the life sciences community developing in the city. JLL, which markets enterprise suites at H-1, brokered the transaction.

